VERTANICAL growth playbook

Update the corporate milestone text in both languages to the factual status (approved in Germany and Austria, launch under way, US studies continuing), in wording Regulatory approves. Keep the brand name and all product information inside the DocCheck portal, and add a clear "For healthcare professionals" entry point near the top of the homepage.

The public site then matches what doctors hear from the field team, and they reach the portal in one click without the company promoting a prescription medicine to the public.

[ ] German milestone sentence updated (approval, not application)
[ ] English milestone sentence updated
[ ] Pipeline status matches the approval
[ ] No product claims or brand promotion on public pages
[ ] "Für Fachkreise" entry point above the fold
[ ] Regulatory and legal sign-off recorded
[ ] Field team briefed

• Wording could read as promotion

  Regulatory signs off; product information stays behind the login.

• Status differs by country

  State approval only for Germany and Austria.

• Your websiteGerman homepage (sitemap last modified August 30, 2025): "Mit dem Antrag auf Zulassung von VER-01 als Fertigarzneimittel zur Behandlung chronischer Kreuzschmerzen haben wir einen bedeutenden Meilenstein erreicht" (the application, not the approval); it does not mention the approval or the name Exilby. The pipeline lists six chronic low back pain studies, including ELEVATE against opioids, with osteoarthritis and diabetic neuropathy studies "Geplant".Source
• Your websiteEnglish homepage: "With the submission of our marketing application for the approval of VER-01 in Germany we have reached an important milestone"; no English area for healthcare professionals: its "Fachkreise" link leads to the German-language portal.Source
• Your websitePress page: "Mit der Zulassung unseres ersten Fertigarzneimittels haben wir ... einen wichtigen Meilenstein" reached; lists "VERTANICAL erhält Zulassung" (June 9, 2026), the FDA Breakthrough Therapy designation (May 18, 2026), the German Pain and Palliative Care Days in Frankfurt 2026 and coverage in Bloomberg, Forbes, Business Insider, WELT, BILD and ntv. Each release opens in a pop-up from a "#" link; the approval release's own page is set to noindex, nofollow and nosnippet and is not in the sitemap.Source
• HiringEvery VERTANICAL post says VER-01, a cannabinoid-based medicine for chronic pain, "was approved in June 2026 under the name Exilby in Germany and Austria"; "approval in the USA is planned for 2029", and the goal is to establish Exilby as a leading chronic pain therapy by 2030 (translated). Applications go to FUTRUE GmbH in Gräfelfing.Source
• Hiring(Senior) Manager Scientific Marketing/Medical Affairs (Gräfelfing, posted September 23, 2026; German post, translated): develops "medical-scientific communication concepts and materials for communication with doctors and pharmacists", analyses competitors' marketing, plans events and congresses "initially focused on Germany but increasingly with an international component", builds formats for KOLs, prepares study results for the trade press, and answers "medical enquiries from doctors and pharmacists" with quality-assured responses agreed with Regulatory and Clinical Trials.Source

Add a required "I am" choice (doctor, pharmacist, other healthcare professional, patient or relative, press, applicant). Route healthcare professionals to Medical Affairs with a documented reply, patients to a standard answer that points them to their doctor and to the adverse event page, press to PR. Have Regulatory decide what, if anything, the "Updates" option may send to non-professionals.

Medical enquiries get answered properly and on record, and the company avoids sending product information to the public by accident.

• Adverse events arrive through the form

  Forward them to pharmacovigilance the same day.

• Your websiteContact page: one form (first name, last name, postcode, city, email, message and an "Updates" option) for every kind of enquiry, with press enquiries to a PR address; a separate "Nebenwirkungsmeldung" (adverse event report) page sits in the main menu.Source
• Hiring(Senior) Manager Scientific Marketing/Medical Affairs (Gräfelfing, posted September 23, 2026; German post, translated): develops "medical-scientific communication concepts and materials for communication with doctors and pharmacists", analyses competitors' marketing, plans events and congresses "initially focused on Germany but increasingly with an international component", builds formats for KOLs, prepares study results for the trade press, and answers "medical enquiries from doctors and pharmacists" with quality-assured responses agreed with Regulatory and Clinical Trials.Source
• Your websiteFachkreise portal: content "richten sich ausschließlich an Ärztinnen, Ärzte und medizinische Fachkreise"; access after DocCheck login (or a Microsoft company account); sections for product information, chronic low back pain, events, information and services, and contact (published August 28, 2026). The portal is in German only.Source
• HiringOther open roles: Team Lead/Director Regulatory Affairs, Quality Assurance and CMC (October 6, 2026), (Junior) Managers Regulatory Affairs and Quality Assurance/Pharmacovigilance (October 22), a pharmacovigilance working student, Directors of Clinical Development (including "selection of new indications"), Clinical Strategy, Clinical Operations and Clinical Data Management & Biostatistics, and a team assistant focused on event management (September 23).Source

Give each corporate release (FDA designation, events, visits, statements) a normal page with a date and a press contact, and add a media kit (logos, company facts, executive photos). Let Regulatory decide, release by release, which product-related news stays out of search, as the approval release does now.

Journalists and partners can cite and share the company's news, while product-related news stays under regulatory control.

• Product claims in corporate news

  Regulatory checks each release before it gets a page.

• Your websitePress page: "Mit der Zulassung unseres ersten Fertigarzneimittels haben wir ... einen wichtigen Meilenstein" reached; lists "VERTANICAL erhält Zulassung" (June 9, 2026), the FDA Breakthrough Therapy designation (May 18, 2026), the German Pain and Palliative Care Days in Frankfurt 2026 and coverage in Bloomberg, Forbes, Business Insider, WELT, BILD and ntv. Each release opens in a pop-up from a "#" link; the approval release's own page is set to noindex, nofollow and nosnippet and is not in the sitemap.Source
• Your websiteSitemap (18 URLs, checked October 22, 2026): the homepage, eight Fachkreise portal pages, press, careers, imprint and contact in German and English. No separate pages for the pipeline, the studies, study centres or the team; the careers page says previous pharma experience "ist nicht erforderlich" and links to the Ashby board.Source
• News coverageBloomberg, June 10, 2026: "Cannabis medicine for back pain aims to displace opioids" (headline from the article address, linked from the VERTANICAL homepage).Source

Name pharmacists in the portal's welcome text, check that DocCheck access works for them, and add a pharmacy section with the practical information Regulatory approves for pharmacists (product information, ordering and storage, who to contact).

Pharmacists who know how to handle a new medicine avoid problems at the counter for prescribing doctors.

• Wrong information for a profession

  Regulatory approves each section.

• Hiring(Senior) Manager Scientific Marketing/Medical Affairs (Gräfelfing, posted September 23, 2026; German post, translated): develops "medical-scientific communication concepts and materials for communication with doctors and pharmacists", analyses competitors' marketing, plans events and congresses "initially focused on Germany but increasingly with an international component", builds formats for KOLs, prepares study results for the trade press, and answers "medical enquiries from doctors and pharmacists" with quality-assured responses agreed with Regulatory and Clinical Trials.Source
• Your websiteFachkreise portal: content "richten sich ausschließlich an Ärztinnen, Ärzte und medizinische Fachkreise"; access after DocCheck login (or a Microsoft company account); sections for product information, chronic low back pain, events, information and services, and contact (published August 28, 2026). The portal is in German only.Source

Link the adverse event page from the contact form, the portal's every page and the footer; add the reporting route to field materials and congress stands; and make sure reports from any channel reach pharmacovigilance the same day.

Reliable safety reporting protects patients and the approval, and shows doctors the company takes it seriously.

• Reports lost in general inboxes

  Daily checks of shared inboxes.

• Your websiteContact page: one form (first name, last name, postcode, city, email, message and an "Updates" option) for every kind of enquiry, with press enquiries to a PR address; a separate "Nebenwirkungsmeldung" (adverse event report) page sits in the main menu.Source
• HiringOther open roles: Team Lead/Director Regulatory Affairs, Quality Assurance and CMC (October 6, 2026), (Junior) Managers Regulatory Affairs and Quality Assurance/Pharmacovigilance (October 22), a pharmacovigilance working student, Directors of Clinical Development (including "selection of new indications"), Clinical Strategy, Clinical Operations and Clinical Data Management & Biostatistics, and a team assistant focused on event management (September 23).Source
• Your websiteFachkreise portal: content "richten sich ausschließlich an Ärztinnen, Ärzte und medizinische Fachkreise"; access after DocCheck login (or a Microsoft company account); sections for product information, chronic low back pain, events, information and services, and contact (published August 28, 2026). The portal is in German only.Source

Inside the portal, add a postcode lookup that shows the territory's representative and a request form for a practice training or materials. Route requests to the representative's CRM queue and follow up within two working days.

Doctors who ask for a visit are the best use of a representative's time, especially in territories that are still being filled.

• Unfilled territories

  Route to the inside team until the post is filled.

• Co-promotion overlap

  Agree with the co-promotion partner who answers which area.

• HiringMedical field representatives (Germany, posted August 23, 2026) for five territories in Baden-Württemberg and Bavaria (for example Augsburg - Aichach - Günzburg and Rosenheim - Geretsried - Traunstein): train specialists, GPs and hospital doctors in practices and clinics, organise referrer events ("Zuweiser-Veranstaltungen") and build contact with regional opinion leaders; candidates need the qualification under section 75 of the German Medicines Act.Source
• Your websiteFachkreise portal: content "richten sich ausschließlich an Ärztinnen, Ärzte und medizinische Fachkreise"; access after DocCheck login (or a Microsoft company account); sections for product information, chronic low back pain, events, information and services, and contact (published August 28, 2026). The portal is in German only.Source
• Your websiteCo-promotion privacy notice: Viatris (Viatris Healthcare GmbH and Viatris Germany GmbH) and Vertanical GmbH, "Inhaberin der arzneimittelrechtlichen Zulassung" for Exilby, are joint controllers for promoting Exilby to healthcare professionals; healthcare professional data comes from IQVIA and direct + online GmbH.Source

Create an approved event kit: invitation templates, a slide deck approved by Regulatory, a speaker briefing, attendance and consent forms, and a post-event survey. Register events in the portal's events section for logged-in doctors.

Consistent, approved events are faster to run and safer, and the survey shows which formats work.

• Off-label questions at events

  Speakers briefed to refer them to Medical Affairs.

• HiringMedical field representatives (Germany, posted August 23, 2026) for five territories in Baden-Württemberg and Bavaria (for example Augsburg - Aichach - Günzburg and Rosenheim - Geretsried - Traunstein): train specialists, GPs and hospital doctors in practices and clinics, organise referrer events ("Zuweiser-Veranstaltungen") and build contact with regional opinion leaders; candidates need the qualification under section 75 of the German Medicines Act.Source
• HiringOther open roles: Team Lead/Director Regulatory Affairs, Quality Assurance and CMC (October 6, 2026), (Junior) Managers Regulatory Affairs and Quality Assurance/Pharmacovigilance (October 22), a pharmacovigilance working student, Directors of Clinical Development (including "selection of new indications"), Clinical Strategy, Clinical Operations and Clinical Data Management & Biostatistics, and a team assistant focused on event management (September 23).Source
• Your websiteFachkreise portal: content "richten sich ausschließlich an Ärztinnen, Ärzte und medizinische Fachkreise"; access after DocCheck login (or a Microsoft company account); sections for product information, chronic low back pain, events, information and services, and contact (published August 28, 2026). The portal is in German only.Source
• Hiring(Senior) Manager Scientific Marketing/Medical Affairs (Gräfelfing, posted September 23, 2026; German post, translated): develops "medical-scientific communication concepts and materials for communication with doctors and pharmacists", analyses competitors' marketing, plans events and congresses "initially focused on Germany but increasingly with an international component", builds formats for KOLs, prepares study results for the trade press, and answers "medical enquiries from doctors and pharmacists" with quality-assured responses agreed with Regulatory and Clinical Trials.Source

Log every enquiry, write approved standard answers for the most common questions, publish them as a searchable FAQ inside the portal, and set a response-time target. Review gaps monthly with the MSL team.

Fast, consistent answers build trust with prescribers and free medical staff for complex questions.

• Answers going out of date

  Date each answer and review quarterly.

• Hiring(Senior) Manager Scientific Marketing/Medical Affairs (Gräfelfing, posted September 23, 2026; German post, translated): develops "medical-scientific communication concepts and materials for communication with doctors and pharmacists", analyses competitors' marketing, plans events and congresses "initially focused on Germany but increasingly with an international component", builds formats for KOLs, prepares study results for the trade press, and answers "medical enquiries from doctors and pharmacists" with quality-assured responses agreed with Regulatory and Clinical Trials.Source
• Hiring(Senior) Medical Science Liaison Manager (posted September 23, 2026): the contact for "leading opinion makers in pain therapy in Germany and internationally", presents scientific data, develops KOL exchange formats and attends congresses, and is "hands-on involved in the market launch" (translated).Source
• Your websiteFachkreise portal: content "richten sich ausschließlich an Ärztinnen, Ärzte und medizinische Fachkreise"; access after DocCheck login (or a Microsoft company account); sections for product information, chronic low back pain, events, information and services, and contact (published August 28, 2026). The portal is in German only.Source

Map pain specialists by region and focus, run two advisory boards a year, build a trained speaker network for congresses and referrer events, and document every engagement under the applicable codes for working with healthcare professionals.

Peer voices carry weight with doctors, and a speaker network scales the field team's events.

• Transparency rules on payments

  Record and disclose as the codes require.

• Hiring(Senior) Medical Science Liaison Manager (posted September 23, 2026): the contact for "leading opinion makers in pain therapy in Germany and internationally", presents scientific data, develops KOL exchange formats and attends congresses, and is "hands-on involved in the market launch" (translated).Source
• HiringMedical field representatives (Germany, posted August 23, 2026) for five territories in Baden-Württemberg and Bavaria (for example Augsburg - Aichach - Günzburg and Rosenheim - Geretsried - Traunstein): train specialists, GPs and hospital doctors in practices and clinics, organise referrer events ("Zuweiser-Veranstaltungen") and build contact with regional opinion leaders; candidates need the qualification under section 75 of the German Medicines Act.Source
• Hiring(Senior) Manager Scientific Marketing/Medical Affairs (Gräfelfing, posted September 23, 2026; German post, translated): develops "medical-scientific communication concepts and materials for communication with doctors and pharmacists", analyses competitors' marketing, plans events and congresses "initially focused on Germany but increasingly with an international component", builds formats for KOLs, prepares study results for the trade press, and answers "medical enquiries from doctors and pharmacists" with quality-assured responses agreed with Regulatory and Clinical Trials.Source

Plan a yearly calendar of pain congresses, set a goal for each, and capture healthcare professional contacts with consent so they can receive a portal invitation and a representative visit afterwards. Report contacts and follow-ups per congress.

Congress follow-up turns short conversations into portal users and practice visits.

• Contacts without consent

  Capture consent at the booth, not later.

• Hiring(Senior) Manager Scientific Marketing/Medical Affairs (Gräfelfing, posted September 23, 2026; German post, translated): develops "medical-scientific communication concepts and materials for communication with doctors and pharmacists", analyses competitors' marketing, plans events and congresses "initially focused on Germany but increasingly with an international component", builds formats for KOLs, prepares study results for the trade press, and answers "medical enquiries from doctors and pharmacists" with quality-assured responses agreed with Regulatory and Clinical Trials.Source
• Your websitePress page: "Mit der Zulassung unseres ersten Fertigarzneimittels haben wir ... einen wichtigen Meilenstein" reached; lists "VERTANICAL erhält Zulassung" (June 9, 2026), the FDA Breakthrough Therapy designation (May 18, 2026), the German Pain and Palliative Care Days in Frankfurt 2026 and coverage in Bloomberg, Forbes, Business Insider, WELT, BILD and ntv. Each release opens in a pop-up from a "#" link; the approval release's own page is set to noindex, nofollow and nosnippet and is not in the sitemap.Source
• Your websiteFachkreise portal: content "richten sich ausschließlich an Ärztinnen, Ärzte und medizinische Fachkreise"; access after DocCheck login (or a Microsoft company account); sections for product information, chronic low back pain, events, information and services, and contact (published August 28, 2026). The portal is in German only.Source

Publish a short, approved digest of each publication in the portal with a link to the paper, and run a quarterly online journal club where an independent expert discusses the data with questions from attendees.

Doctors learn the evidence from the source, and the journal club brings them back to the portal.

• Summaries go beyond the label

  Regulatory approves every summary.

• Hiring(Senior) Manager Scientific Marketing/Medical Affairs (Gräfelfing, posted September 23, 2026; German post, translated): develops "medical-scientific communication concepts and materials for communication with doctors and pharmacists", analyses competitors' marketing, plans events and congresses "initially focused on Germany but increasingly with an international component", builds formats for KOLs, prepares study results for the trade press, and answers "medical enquiries from doctors and pharmacists" with quality-assured responses agreed with Regulatory and Clinical Trials.Source
• Hiring(Senior) Medical Science Liaison Manager (posted September 23, 2026): the contact for "leading opinion makers in pain therapy in Germany and internationally", presents scientific data, develops KOL exchange formats and attends congresses, and is "hands-on involved in the market launch" (translated).Source
• Your websitePress page: "Mit der Zulassung unseres ersten Fertigarzneimittels haben wir ... einen wichtigen Meilenstein" reached; lists "VERTANICAL erhält Zulassung" (June 9, 2026), the FDA Breakthrough Therapy designation (May 18, 2026), the German Pain and Palliative Care Days in Frankfurt 2026 and coverage in Bloomberg, Forbes, Business Insider, WELT, BILD and ntv. Each release opens in a pop-up from a "#" link; the approval release's own page is set to noindex, nofollow and nosnippet and is not in the sitemap.Source
• Your websiteFachkreise portal: content "richten sich ausschließlich an Ärztinnen, Ärzte und medizinische Fachkreise"; access after DocCheck login (or a Microsoft company account); sections for product information, chronic low back pain, events, information and services, and contact (published August 28, 2026). The portal is in German only.Source

Add three fields to the visit report (top question, material requested, objection), review them monthly with scientific marketing and Medical Affairs, and add or update portal content for the most common themes.

Content that answers real questions gets used, and representatives see their feedback turn into tools.

• Medical questions answered by reps

  Reps pass medical questions to Medical Affairs.

• HiringMedical field representatives (Germany, posted August 23, 2026) for five territories in Baden-Württemberg and Bavaria (for example Augsburg - Aichach - Günzburg and Rosenheim - Geretsried - Traunstein): train specialists, GPs and hospital doctors in practices and clinics, organise referrer events ("Zuweiser-Veranstaltungen") and build contact with regional opinion leaders; candidates need the qualification under section 75 of the German Medicines Act.Source
• Hiring(Senior) Manager Scientific Marketing/Medical Affairs (Gräfelfing, posted September 23, 2026; German post, translated): develops "medical-scientific communication concepts and materials for communication with doctors and pharmacists", analyses competitors' marketing, plans events and congresses "initially focused on Germany but increasingly with an international component", builds formats for KOLs, prepares study results for the trade press, and answers "medical enquiries from doctors and pharmacists" with quality-assured responses agreed with Regulatory and Clinical Trials.Source
• Your websiteFachkreise portal: content "richten sich ausschließlich an Ärztinnen, Ärzte und medizinische Fachkreise"; access after DocCheck login (or a Microsoft company account); sections for product information, chronic low back pain, events, information and services, and contact (published August 28, 2026). The portal is in German only.Source

Agree a shared calendar of campaigns, events and materials; split or coordinate territories and target lists; use one approved core message and one medical enquiry route; and review results together each month.

Doctors get a consistent experience, neither team wastes visits, and the launch reaches more practices.

• Data sharing rules

  Follow the joint-controller notice for what is shared.

• Your websiteCo-promotion privacy notice: Viatris (Viatris Healthcare GmbH and Viatris Germany GmbH) and Vertanical GmbH, "Inhaberin der arzneimittelrechtlichen Zulassung" for Exilby, are joint controllers for promoting Exilby to healthcare professionals; healthcare professional data comes from IQVIA and direct + online GmbH.Source
• HiringMedical field representatives (Germany, posted August 23, 2026) for five territories in Baden-Württemberg and Bavaria (for example Augsburg - Aichach - Günzburg and Rosenheim - Geretsried - Traunstein): train specialists, GPs and hospital doctors in practices and clinics, organise referrer events ("Zuweiser-Veranstaltungen") and build contact with regional opinion leaders; candidates need the qualification under section 75 of the German Medicines Act.Source
• Hiring(Senior) Manager Scientific Marketing/Medical Affairs (Gräfelfing, posted September 23, 2026; German post, translated): develops "medical-scientific communication concepts and materials for communication with doctors and pharmacists", analyses competitors' marketing, plans events and congresses "initially focused on Germany but increasingly with an international component", builds formats for KOLs, prepares study results for the trade press, and answers "medical enquiries from doctors and pharmacists" with quality-assured responses agreed with Regulatory and Clinical Trials.Source

Check with Regulatory what Austrian healthcare professionals need (local product information, the local marketing contact, reporting routes), add an Austria section to the portal, and name who serves Austrian doctors until there is a local field presence.

Austrian doctors who hear about the approval can get information and a contact without guessing.

• Different rules in Austria

  Regulatory checks every Austrian text.

• HiringEvery VERTANICAL post says VER-01, a cannabinoid-based medicine for chronic pain, "was approved in June 2026 under the name Exilby in Germany and Austria"; "approval in the USA is planned for 2029", and the goal is to establish Exilby as a leading chronic pain therapy by 2030 (translated). Applications go to FUTRUE GmbH in Gräfelfing.Source
• HiringMedical field representatives (Germany, posted August 23, 2026) for five territories in Baden-Württemberg and Bavaria (for example Augsburg - Aichach - Günzburg and Rosenheim - Geretsried - Traunstein): train specialists, GPs and hospital doctors in practices and clinics, organise referrer events ("Zuweiser-Veranstaltungen") and build contact with regional opinion leaders; candidates need the qualification under section 75 of the German Medicines Act.Source
• Your websiteFachkreise portal: content "richten sich ausschließlich an Ärztinnen, Ärzte und medizinische Fachkreise"; access after DocCheck login (or a Microsoft company account); sections for product information, chronic low back pain, events, information and services, and contact (published August 28, 2026). The portal is in German only.Source
• Your websiteContact page: one form (first name, last name, postcode, city, email, message and an "Updates" option) for every kind of enquiry, with press enquiries to a PR address; a separate "Nebenwirkungsmeldung" (adverse event report) page sits in the main menu.Source

Offer verified portal users an opt-in for short emails when new materials, events or answers are added. Keep the list separate from any public contact list, and let users choose topics (studies, events, practice information).

Returning users see new evidence and events, which keeps the medicine in mind between representative visits.

• Emails reach non-professionals

  Send only to verified portal users who opted in.

• Your websiteFachkreise portal: content "richten sich ausschließlich an Ärztinnen, Ärzte und medizinische Fachkreise"; access after DocCheck login (or a Microsoft company account); sections for product information, chronic low back pain, events, information and services, and contact (published August 28, 2026). The portal is in German only.Source
• Hiring(Senior) Manager Scientific Marketing/Medical Affairs (Gräfelfing, posted September 23, 2026; German post, translated): develops "medical-scientific communication concepts and materials for communication with doctors and pharmacists", analyses competitors' marketing, plans events and congresses "initially focused on Germany but increasingly with an international component", builds formats for KOLs, prepares study results for the trade press, and answers "medical enquiries from doctors and pharmacists" with quality-assured responses agreed with Regulatory and Clinical Trials.Source
• Your websiteContact page: one form (first name, last name, postcode, city, email, message and an "Updates" option) for every kind of enquiry, with press enquiries to a PR address; a separate "Nebenwirkungsmeldung" (adverse event report) page sits in the main menu.Source

Track, with consent and in line with the privacy notice, the steps from homepage to login, login completion, and use of each section and download. Report monthly to scientific marketing and the field team.

Clear numbers show where professionals drop off and which materials earn their place.

• Tracking without consent

  Only what the consent banner allows.

• Your websiteFachkreise portal: content "richten sich ausschließlich an Ärztinnen, Ärzte und medizinische Fachkreise"; access after DocCheck login (or a Microsoft company account); sections for product information, chronic low back pain, events, information and services, and contact (published August 28, 2026). The portal is in German only.Source
• Google PageSpeedMobile performance score 98; real Chrome visitors pass Core Web Vitals (largest contentful paint 0.9 s, interaction to next paint 105 ms, layout shift 0).Source
• Your websiteGerman homepage (sitemap last modified August 30, 2025): "Mit dem Antrag auf Zulassung von VER-01 als Fertigarzneimittel zur Behandlung chronischer Kreuzschmerzen haben wir einen bedeutenden Meilenstein erreicht" (the application, not the approval); it does not mention the approval or the name Exilby. The pipeline lists six chronic low back pain studies, including ELEVATE against opioids, with osteoarthritis and diabetic neuropathy studies "Geplant".Source

Write a reusable launch playbook: regulatory status page per country, local-language portal section, opinion-leader map, congress plan, enquiry and safety routes, and partner model. Launch nothing in a country before its approval, and keep each country's content separate.

A repeatable launch shortens the time from each approval to the first prescriptions.

• Content reaching countries without approval

  Gate portal sections by country.

• Hiring(Senior) Manager Scientific Marketing/Medical Affairs (Gräfelfing, posted September 23, 2026; German post, translated): develops "medical-scientific communication concepts and materials for communication with doctors and pharmacists", analyses competitors' marketing, plans events and congresses "initially focused on Germany but increasingly with an international component", builds formats for KOLs, prepares study results for the trade press, and answers "medical enquiries from doctors and pharmacists" with quality-assured responses agreed with Regulatory and Clinical Trials.Source
• HiringEvery VERTANICAL post says VER-01, a cannabinoid-based medicine for chronic pain, "was approved in June 2026 under the name Exilby in Germany and Austria"; "approval in the USA is planned for 2029", and the goal is to establish Exilby as a leading chronic pain therapy by 2030 (translated). Applications go to FUTRUE GmbH in Gräfelfing.Source
• Your websitePress page: "Mit der Zulassung unseres ersten Fertigarzneimittels haben wir ... einen wichtigen Meilenstein" reached; lists "VERTANICAL erhält Zulassung" (June 9, 2026), the FDA Breakthrough Therapy designation (May 18, 2026), the German Pain and Palliative Care Days in Frankfurt 2026 and coverage in Bloomberg, Forbes, Business Insider, WELT, BILD and ntv. Each release opens in a pop-up from a "#" link; the approval release's own page is set to noindex, nofollow and nosnippet and is not in the sitemap.Source
• Your websiteFachkreise portal: content "richten sich ausschließlich an Ärztinnen, Ärzte und medizinische Fachkreise"; access after DocCheck login (or a Microsoft company account); sections for product information, chronic low back pain, events, information and services, and contact (published August 28, 2026). The portal is in German only.Source

Build an English scientific page about the research programme (studies with their registry numbers, publications, contact for investigators and medical information), approved by Regulatory for a US audience, and plan a medical-affairs presence at US pain congresses. Use investigational wording throughout.

US researchers, investigators and future partners can find accurate information, which supports trial recruitment and partnering.

• Reading as US promotion

  Investigational wording and Regulatory sign-off.

• HiringEvery VERTANICAL post says VER-01, a cannabinoid-based medicine for chronic pain, "was approved in June 2026 under the name Exilby in Germany and Austria"; "approval in the USA is planned for 2029", and the goal is to establish Exilby as a leading chronic pain therapy by 2030 (translated). Applications go to FUTRUE GmbH in Gräfelfing.Source
• Your websiteEnglish homepage: "With the submission of our marketing application for the approval of VER-01 in Germany we have reached an important milestone"; no English area for healthcare professionals: its "Fachkreise" link leads to the German-language portal.Source
• Your websitePress page: "Mit der Zulassung unseres ersten Fertigarzneimittels haben wir ... einen wichtigen Meilenstein" reached; lists "VERTANICAL erhält Zulassung" (June 9, 2026), the FDA Breakthrough Therapy designation (May 18, 2026), the German Pain and Palliative Care Days in Frankfurt 2026 and coverage in Bloomberg, Forbes, Business Insider, WELT, BILD and ntv. Each release opens in a pop-up from a "#" link; the approval release's own page is set to noindex, nofollow and nosnippet and is not in the sitemap.Source
• Your websiteGerman homepage (sitemap last modified August 30, 2025): "Mit dem Antrag auf Zulassung von VER-01 als Fertigarzneimittel zur Behandlung chronischer Kreuzschmerzen haben wir einen bedeutenden Meilenstein erreicht" (the application, not the approval); it does not mention the approval or the name Exilby. The pipeline lists six chronic low back pain studies, including ELEVATE against opioids, with osteoarthritis and diabetic neuropathy studies "Geplant".Source

Publish a page for investigators: the planned study areas in neutral wording, what VERTANICAL looks for in a centre, and a short expression-of-interest form routed to Clinical Operations. Link it from the pipeline section.

Faster site selection shortens study timelines, which brings every next indication closer.

• Page read as patient recruitment

  Address investigators only; no patient sign-up.

• Your websiteGerman homepage (sitemap last modified August 30, 2025): "Mit dem Antrag auf Zulassung von VER-01 als Fertigarzneimittel zur Behandlung chronischer Kreuzschmerzen haben wir einen bedeutenden Meilenstein erreicht" (the application, not the approval); it does not mention the approval or the name Exilby. The pipeline lists six chronic low back pain studies, including ELEVATE against opioids, with osteoarthritis and diabetic neuropathy studies "Geplant".Source
• HiringOther open roles: Team Lead/Director Regulatory Affairs, Quality Assurance and CMC (October 6, 2026), (Junior) Managers Regulatory Affairs and Quality Assurance/Pharmacovigilance (October 22), a pharmacovigilance working student, Directors of Clinical Development (including "selection of new indications"), Clinical Strategy, Clinical Operations and Clinical Data Management & Biostatistics, and a team assistant focused on event management (September 23).Source
• Your websiteSitemap (18 URLs, checked October 22, 2026): the homepage, eight Fachkreise portal pages, press, careers, imprint and contact in German and English. No separate pages for the pipeline, the studies, study centres or the team; the careers page says previous pharma experience "ist nicht erforderlich" and links to the Ashby board.Source

Create a short careers page per open territory (towns covered, what the job involves, a day in the field), link it from the careers page and share it in local job searches. Track applications by territory.

Territories filled faster mean doctors are visited sooner after launch.

• Pages stay up after hiring

  Remove them when a territory is filled.

• HiringMedical field representatives (Germany, posted August 23, 2026) for five territories in Baden-Württemberg and Bavaria (for example Augsburg - Aichach - Günzburg and Rosenheim - Geretsried - Traunstein): train specialists, GPs and hospital doctors in practices and clinics, organise referrer events ("Zuweiser-Veranstaltungen") and build contact with regional opinion leaders; candidates need the qualification under section 75 of the German Medicines Act.Source
• Your websiteSitemap (18 URLs, checked October 22, 2026): the homepage, eight Fachkreise portal pages, press, careers, imprint and contact in German and English. No separate pages for the pipeline, the studies, study centres or the team; the careers page says previous pharma experience "ist nicht erforderlich" and links to the Ashby board.Source
• Parent companyVERTANICAL belongs to the FUTRUE group in Gräfelfing near Munich; the group's job boards list VERTANICAL roles alongside FUTRUE, Kijimea and FUTRUE Neurosciences, all posted in German.Source